Cedarburg Hauser adds plant capacity

Wednesday, September 26, 2012 09:32 AM

Cedarburg Hauser Pharmaceuticals (CHP), a Grafton, Wisc.-based contract development and manufacturing organization, has expanded the capacity of its active pharmaceutical ingredient (API) manufacturing plant in Wisconsin.

The expansion efforts are a result of an increased demand for contract manufacturing of commercial APIs and are accompanied by additional upgrades aimed at improving safety and GMP systems.

“These improvements increase our total reactor capacity by nearly 50%,” said John Flahive, CHP’s newly hired director of operations. “We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs.”

In addition to the new reactors, CHP has also made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved isolation capabilities and upgraded their Emerson DeltaV Digital Automation System.

“The added reactor capacity and upgrades to existing safety and GMP systems are the latest example of Cedarburg Hauser’s continued commitment to serving the commercial API marketplace,” said Tony Laughrey, CEO of CHP. “The flexibility afforded by the additional reactor capacity allows us to better meet our customer’s on-time and on-budget requirements.”

Share:          
CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs